PeptiDream Inc.

Business Details

Leveraging its proprietary drug discovery platform system PDPS®, the company pursues a three-pronged business strategy: (1) joint drug discovery R&D, (2) PDPS® technology licensing, and (3) expansion of its in-house pipeline through strategic partnerships. Main revenue sources are contract upfront fees, milestone fees, and royalties related to PDPS licensing, as well as R&D support income. The company has entered into non-exclusive technology license agreements with 11 major global pharmaceutical companies including BMS, Novartis, Lilly, MSD, and AstraZeneca. It is expanding its pipeline across both the Non-RI field (peptide drugs, PDCs, MPCs) and the RI-PDC field.

Recent Overview

Q1 revenue rose 64.5% year-on-year to ¥670 million, with a narrower loss

Revenue from the Drug Discovery Development Business in Q1 FY2026 (ending March 2026) increased significantly to ¥670 million (versus ¥407 million in the same period last year). This was mainly driven by a sharp increase in product manufacturing, sales, and logistics income to ¥295 million (versus ¥24 million in the same period last year). Segment loss improved by ¥235 million to ¥1,193 million (versus ¥1,428 million in the same period last year). Note that no contract upfront fees, milestone, or royalty income was recorded this quarter either. In April 2026, Asahi Kasei Pharma's AK1940 began Phase 1 clinical trials, and the first development candidate compound from the joint research with J&J was announced in January 2026.

Key Products

Growth Drivers

• Future increase in milestone income due to rapid expansion of the clinical development pipeline (start of AK1940 Phase 1, announcement of J&J development candidate compound, etc.)
• Opportunities to obtain contract upfront fees through out-licensing or partnering of in-house programs such as the oral myostatin inhibitor and oral IL-17A/F dual inhibitor
• Receipt of milestone fees tied to clinical progress of existing partnered programs with Novartis, RayzeBio/BMS, Genentech, MSD, J&J, Asahi Kasei Pharma, and others
• Continued license fee and royalty income from the 11 companies licensing PDPS® technology, and conclusion of new license agreements
• Progression to the next phase through achievement of preclinical milestones in siRNA delivery technology to organs other than the liver (Oligo-PDC) with Alnylam

Risks

• Risk of significant fluctuation in single-year results due to uncertain timing of recognition of large out-licensing upfront fees and milestones (major out-licensing upfronts are not included in the full-year FY2026 earnings forecast)
• Risk of loss of milestone fee and royalty income due to discontinuation of development or reprioritization by partner pharmaceutical companies
• Risk of impairment to the value of the in-house pipeline due to failure or delay of clinical trials
• Risk of expanding losses due to costs preceding monetization, with R&D expenses expected to increase 28.3% year-on-year to ¥6,445 million for full-year FY2026
• Governance risk stemming from an issue involving improper ordering and removal of reagents by a former Representative Director and COO (financial impact is minor, but recurrence prevention measures are being implemented)